Skip to main content
. 2013 Feb 28;12(6):1621–1631. doi: 10.1074/mcp.M112.026427

Fig. 3.

Fig. 3.

Single agent behavior of sorafenib and bevacizumab. A, fold-change in activation of p-ERK in tumor protein expression occurring in patients receiving either 2 weeks of single agent sorafenib (left group) or bevacizumab (right group) is shown (p < 0.02). B, CD31+ cells per high power field in tumor in patients receiving either 2 weeks of single agent sorafenib or bevacizumab is shown (p < 0.05).